Targeting acid ceramidase inhibits YAP/TAZ signaling to reduce fibrosis in mice

Hepatic stellate cells (HSCs) drive hepatic fibrosis. Therapies that inactivate HSCs have clinical potential as antifibrotic agents. We previously identified acid ceramidase (aCDase) as an antifibrotic target. We showed that tricyclic antidepressants (TCAs) reduce hepatic fibrosis by inhibiting aCDase and increasing the bioactive sphingolipid ceramide. We now demonstrate that targeting aCDase inhibits YAP/TAZ activity by potentiating its phosphorylation-mediated proteasomal degradation via the ubiquitin ligase adaptor protein β-TrCP. In mouse models of fibrosis, pharmacologic inhibition of aCDase or genetic knockout of aCDase in HSCs reduces fibrosis, stromal stiffness, and YAP/TAZ activity. In patients with advanced fibrosis, aCDase expression in HSCs is increased. Consistently, a signature of the genes most down-regulated by ceramide identifies patients with advanced fibrosis who could benefit from aCDase targeting. The findings implicate ceramide as a critical regulator of YAP/TAZ signaling and HSC activation and highlight aCDase as a therapeutic target for the treatment of fibrosis.

Effects of different goal orientations and virtual opponents performance level on pacing strategy and performance in cycling time trials

We investigated the effects of different performance goals (best time vs. beat the opponent) on pacing behaviour during a 10-km cycling race and explored the influence of different performance level of opponents on ratings of perceived exertion (RPE), affective feelings and self-efficacy. Thirteen cyclists performed two time-trials (TT) and two races against a faster (FAST +6%) or a slower (SLOW -3%) virtual opponent. Power output (PO), RPE, affective feelings and self-efficacy were recorded at each kilometre point. Race average and race phases [starting (P1 = first kilometre); first half (P2 = 2nd-5th kilometre); second half (P3 = 6th-9th kilometre) and final sprint (FS = last kilometre)] were analysed. There was no difference in performance, assessed by race time between conditions (p = .84). PO during TT was lower in P3 compared to FS (p = .03; ES 0.6; 90%CI 0.4-0.7). In SLOW and FAST, PO was higher in P1 compared to other phases (p < .05). PO in FS was higher in TT compared to FAST (p = .01; ES -0.97; 90%IC -1.4 to -0.5). RPE increased and affective feelings decreased during all conditions. Self-efficacy was stable through TT and SLOW, but decreased during FAST with higher values in P1 compared to P2 (p = .01; ES -1.1; 90%IC -1.6 to -0.6), P3 (p < .001; ES -2.2; 90%IC -2.8 to -1.6) and FS (p < .001; ES -2.6; 90%IC -3.3 to -1.8). Pacing behaviour, specifically starting and final sprint, was affected by virtual opponents independent of performance level, demonstrating the importance of goal orientation. HighlightsAdjustments in exercise intensity result from a complex decision-making process involving physiological, psychological, environmental and tactical information.Goal pursuit is an important determinant of pacing behaviour since athletes must balance their efforts with expectations of success.A competitive environment may be included to motivate participants to maintain their effort and at the same time to improve their self-confidence.The presence of a final sprint seems to be related to the goal orientation and perceived outcomes of success or failure.

Peroxidase Sensitive Amplifiable Probe for Molecular Magnetic Resonance Imaging of Pulmonary Inflammation

An amplifiable magnetic resonance imaging (MRI) probe that combines the stability of the macrocyclic Gd-DOTAGA core with a peroxidase-reactive 5-hydroxytryptamide (5-HT) moiety is reported. The incubation of the complex under enzymatic oxidative conditions led to a 1.7-fold increase in r₁ at 1.4 T that was attributed to an oligomerization of the probe upon oxidation. This probe, Gd-5-HT-DOTAGA, provided specific detection of lung inflammation by MRI in bleomycin-injured mice.

Evaluation of antitumor activity and cardiac toxicity of a bone-targeted ph-sensitive liposomal formulation in a bone metastasis tumor model in mice

Chemotherapy for bone tumors is a major challenge because of the inability of therapeutics to penetrate dense bone mineral. We hypothesize that a nanostructured formulation with high affinity for bone could deliver drug to the tumor while minimizing off-target toxicity. Here, we evaluated the efficacy and toxicity of a novel bone-targeted, pH-sensitive liposomal formulation containing doxorubicin in an animal model of bone metastasis. Biodistribution studies with the liposome showed good uptake in tumor, but low accumulation of doxorubicin in the heart. Mice treated with the bone-targeted liposome formulation showed a 70% reduction in tumor volume, compared to 35% reduction for free doxorubicin at the same dose. Both cardiac toxicity and overall mortality were significantly lower for animals treated with the bone-targeted liposomes compared to free drug. Bone-targeted, pH-sensitive, doxorubicin containing liposomes represent a promising approach to selectively delivering doxorubicin to bone tumors while minimizing cardiac toxicity.